Cilong Chu

Drug-likeness defects drive carrier-free cyanine-PROTAC self-assembly for tumor-specific protein degradation.

Proteolysis-targeting chimeras (PROTACs) offer a powerful strategy for targeted protein degradation but suffer from poor solubility, bioavailability, and in vivo distribution due to their "beyond rule-of-five" physicochemical properties, severely limiting clinical translation. Here, we transform these intrinsic drug-li...